BRIEF-Merck's Efinopegdutide Shows Improvement In Liver Fibrosis Without Worsening Steatohepatitis

2

Nov 9 (Reuters) – Merck & Co Inc: * MERCK ANNOUNCES POSITIVE RESULTS FROM PHASE 2B TRIAL OF EFINOPEGDUTIDE IN ADULTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND STAGE 2-3 FIBROSIS

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)